Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEMCOR.es: bevacizumab 3 vs 1 loading strategy for myopic choroidal neovascularization
2012-001781-15Phase 3Active
- Sponsor
- Universidad de Valladolid
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of bevacizumab in Subretinal neovascularization (2 arms), sponsored by Universidad de Valladolid. Primary endpoint: Best corrected visual acuity. Started May 2012; status: active.
02
Drugs
bevacizumab
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on 2012-001781-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001781-15.